Patents by Inventor Vanessa Hsei

Vanessa Hsei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of binding TNF-? using anti-TNF-? antibody fragment-polymer conjugates
    Patent number: 8652468
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: February 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Methods of binding TNF-alpha using Anti-TNF-alpha antibody fragment-polymer conjugates
    Publication number: 20130084302
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: February 13, 2012
    Publication date: April 4, 2013
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Patent number: 8147830
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • ANTIBODY FRAGMENT-POLYMER CONJUGATES AND USES OF SAME
    Publication number: 20110104185
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: August 4, 2010
    Publication date: May 5, 2011
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Patent number: 7842789
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: November 30, 2010
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Publication number: 20090098147
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: November 12, 2008
    Publication date: April 16, 2009
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Patent number: 7507405
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: March 24, 2009
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Patent number: 7214776
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: May 8, 2007
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Publication number: 20070048219
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: September 28, 2006
    Publication date: March 1, 2007
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Patent number: 7122636
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: October 17, 2006
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and uses of same
    Publication number: 20060083683
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: October 25, 2005
    Publication date: April 20, 2006
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-peg conjugates
    Patent number: 7005504
    Abstract: Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: February 28, 2006
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata
  • Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
    Patent number: 6870033
    Abstract: Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: March 22, 2005
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven R. Leong, Leonard G. Presta, Zahra Shahrokh, Gerarado A. Zapata
  • Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
    Publication number: 20030021790
    Abstract: Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD, The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
    Type: Application
    Filed: November 29, 2000
    Publication date: January 30, 2003
    Applicant: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata
  • Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
    Patent number: 6468532
    Abstract: Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human IL-8, and wherein the apparent size of the conjugate is at least about 500 kD.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: October 22, 2002
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata
  • Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
    Patent number: 6458355
    Abstract: Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human IL-8, and wherein the apparent size of the conjugate is at least about 500 kD.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: October 1, 2002
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata